Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection (AMPLIFY)
2026년 7월 7일 업데이트: Solenic Medical, Inc.
Acute Management of PJI With Local Implant Retention and Antibiotics Using the Sola2 AMF Knee System: A Multicenter Double-blind Clinical Trial.
The goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection.
The main questions this study aims to answer are:
- Whether adding the Sola2 AMF Knee System improves knee function and quality of life at 6 months.
- Whether adding the Sola2 AMF Knee System to surgery and antibiotic treatment affects the need for additional infection-related surgery.
- Whether the Sola2 AMF Knee System can be used safely, based on device-related adverse events through 12 months.
This study has two stages. In Stage 1, participants will be enrolled into sequential sentinel groups at increasing AMF temperature levels. All sentinel participants will receive active Sola2 AMF treatment. A safety review will occur after each sentinel group before proceeding to the next group. In Stage 2, researchers will compare participants who receive active Sola2 AMF treatment to participants who receive sham AMF treatment. All participants will receive surgery called debridement, antibiotics, and implant retention (DAIR), and antibiotic treatment for knee implant infection.
Participants will:
- Have DAIR surgery for knee implant infection;
- Receive pathogen-appropriate antibiotic treatment from the study doctor;
- If enrolled in Stage 1, receive active Sola2 AMF treatment at the designated sentinel temperature level;
- If enrolled in Stage 2, receive either active Sola2 AMF treatment or sham AMF treatment, depending on randomization assignment; and
- Complete follow-up visits and assessments for safety, infection status, pain, knee function, x-rays, laboratory tests, and other study-related outcomes.
연구 개요
상태
아직 모집하지 않음
상세 설명
The AMPLIFY trial is a prospective, multicenter, staged clinical investigation of the investigational Sola2 AMF Knee System in adults with confirmed knee periprosthetic joint infection (PJI) who will undergo debridement, antibiotics, and implant retention (DAIR) surgery and pathogen-appropriate antibiotic therapy.
The study is conducted under a single Investigational Device Exemption and includes two stages. Stage 1 is an open-label sentinel stage using sequential AMF temperature escalation. Sentinel participants receive active Sola2 AMF treatment, with safety review after each sentinel group before progression to the next planned temperature level or to the randomized stage. Stage 2 is a randomized, double-blind, sham-controlled stage in which participants are assigned to active Sola2 AMF treatment or sham AMF treatment.
The Sola2 AMF Knee System is an external, non-contacting investigational device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces. The AMF or sham treatment is administered in the operating room in conjunction with the planned DAIR procedure. All participants receive DAIR and pathogen-appropriate antibiotic therapy as part of their clinical care.
Safety oversight includes medical monitoring, independent Data Safety Monitoring Board review, and independent Clinical Events Committee adjudication as specified in the protocol.
연구 유형
중재적
등록 (추정된)
165
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Vice President Clinical Operations
- 전화번호: 711 U.S.: 877-765-2612
- 이메일: denise.stamos@solenic.com
연구 연락처 백업
- 이름: Chief Medical Officer
- 전화번호: 703 U.S.: 877-765-3612
- 이메일: david.greenberg@solenic.com
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria
Eligible participants must meet all of the following criteria:
- Adult male or female participant aged ≥ 22 years at the time of surgery.
- PJI diagnosis of "infected" knee per the 2018 MSIS Definition of Periprosthetic Hip and Knee Infection.
- Patient presents with PJI symptoms lasting for ≤ 45 days.
- Well-fixed and functioning prosthesis during clinical exam at screening.
- Patient to be treated with DAIR, polyethylene spacer exchange and pathogen- appropriate antibiotic therapy.
- Implanted knee prosthesis must appear on the "AMPLIFY Implant List".
- All implanted knee prosthesis components must have a legible device identification label (implant sticker) available in the medical record.
- Able to comprehend and comply with postoperative instructions and willing to return for follow-up visits for the duration of the study.
- Consent to participate in study and sign the Informed Consent Form (ICF).
Exclusion Criteria
Participants meeting any of the following criteria will be excluded:
- Implanted knee prosthesis not appearing on the "AMPLIFY Implant List".
- Implanted knee prosthesis has any femoral and/or tibial augments, sleeves, cones, or modified/extended stems.
- Un-resurfaced patella.
- Metal-backed patellar components.
- Patients not indicated for a DAIR procedure pre-operatively.
- Patients undergoing bilateral DAIR procedures during the same surgical session.
- Pre-operative determination that the surgical wound cannot be closed primarily and requires a wound vac as a method of wound closure (e.g., open wound managed for secondary intention healing or delayed primary closure); Use of closed-incision negative pressure therapy over a primarily closed incision is permitted.
- Previous DAIR procedure(s) performed on the affected knee joint within the last two years.
- Patients presenting with PJI symptoms lasting for >45 days.
- Patients on antibiotic therapy for an infection other than PJI of the knee.
- Body Mass Index (BMI) ≥ 45.
- Patients currently on bone-marrow suppressive chemotherapy for malignancy.
- Patients currently with active neutropenia.
- Presence of metallic implant(s), other than the femoral and tibial components, within the Sola2 treatment zone (+/- 20 centimeters from the knee joint line) including intramedullary nails, hip prosthesis femoral stem, or fracture fixation hardware.
- Patients with an upper-thigh circumference greater than 70 centimeters (cm) (28 inches (in), measured approximately 15 cm (6 in) proximal to the superior pole of the patella.
- Patients with implanted or nonremovable cardiac pacemakers, defibrillators or cardioverters, insulin pumps, nerve stimulators, or any other indwelling infusion pump.
- Patients who are pregnant or nursing.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 1: Stage 1 Sentinel Group A: Active Sola 2 AMF Treatment 55C
Participants in the first open-label sentinel group receive active Sola2 AMF treatment at the planned 55°C AMF temperature level.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
Safety data are reviewed before progression to the next sentinel group.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
실험적: Arm 2: Stage 1 Sentinel Group B: Active Sola 2 AMF Treatment 60°C
Participants in the second open-label sentinel group receive active Sola2 AMF treatment at the planned 60°C AMF temperature level.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
Enrollment in this group occurs only after safety review supports progression from Sentinel Group A.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
실험적: Arm 3: Stage 1 Sentinel Group C: Active Sola 2 AMF Treatment 65°C
Participants in the third open-label sentinel group receive active Sola2 AMF treatment at the planned 65°C AMF temperature level.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
Enrollment in this group occurs only after safety review supports progression from Sentinel Group B.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
실험적: Arm 4: Stage 2 Randomized Active AMF Treatment
Participants randomized to the active treatment arm receive active Sola2 AMF treatment in conjunction with DAIR and pathogen-appropriate antibiotic therapy.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
가짜 비교기: Arm 5: Stage 2 Randomized Sham AMF Treatment
Participants randomized to the sham treatment arm receive sham AMF treatment in conjunction with DAIR and pathogen-appropriate antibiotic therapy.
Participants undergo the same treatment timing and device-use steps as the active treatment arm, but active AMF energy is not delivered.
|
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
Sham alternating magnetic field treatment is delivered during the randomized stage using the Sola2 AMF Knee System workflow.
The sham treatment uses the same treatment timing and device-use steps as active treatment, without delivery of active alternating magnetic field energy
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement
기간: Baseline to 6 months
|
Change from baseline to 6 months in the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement.
The score is reported using the validated 0 to 100 interval scoring method, with higher scores indicating better knee health.
|
Baseline to 6 months
|
|
Incidence of Infection-Related Surgical Reintervention
기간: From the index DAIR procedure through the primary efficacy analysis, triggered when 24 adjudicated events have occurred and at least 100 participants have completed 12-month follow-up
|
Number and percentage of participants with a qualifying infection-related surgical reintervention event, as adjudicated by an independent Clinical Events Committee.
Qualifying events include surgical reintervention due to relapse or surgical reintervention for ongoing infection, as defined in the protocol.
Only the first adjudicated qualifying surgical reintervention event per participant contributes to the primary endpoint analysis.
|
From the index DAIR procedure through the primary efficacy analysis, triggered when 24 adjudicated events have occurred and at least 100 participants have completed 12-month follow-up
|
|
Incidence of AMF Study Device-Related Adverse Events
기간: Through 12 months post-procedure
|
Number and percentage of participants with one or more adverse events determined to be related to the AMF study device.
Potential primary safety endpoint events are independently adjudicated by the Clinical Events Committee according to the CEC charter.
|
Through 12 months post-procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence, Severity, and Relatedness of Adverse Events and Serious Adverse Events
기간: Through 12 months post-procedure
|
Between-arm comparison of the incidence, severity, and relatedness of adverse events and serious adverse events.
|
Through 12 months post-procedure
|
|
Time to Resolution and Duration of PJI-Related Signs and Symptoms
기간: Through 12 months post-procedure
|
Between-arm comparison of the time to resolution and duration of PJI-related signs and symptoms, such as pain, drainage, erythema, and edema.
|
Through 12 months post-procedure
|
|
Proportion of Participants With Resolution or Marked Improvement of Infection-Related Symptoms
기간: Through 12 months post-procedure
|
Between-arm comparison of the proportion of participants with resolution or marked improvement of infection-related symptoms at scheduled follow-up visits.
|
Through 12 months post-procedure
|
|
Change From Baseline in Numeric Rating Scale Pain Score
기간: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline in participant-reported pain using the Numeric Rating Scale at scheduled follow-up visits.
Scores range from 0 to 10, with higher scores indicating greater pain.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement at Follow-Up Visits Over Time
기간: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement at scheduled follow-up visits other than the 6-month primary endpoint.
Scores are reported using the validated 0 to 100 interval scoring method, with higher scores indicating better knee health.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System Patient-Reported Health Status
기간: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline in Patient-Reported Outcomes Measurement Information System patient-reported health status at scheduled follow-up visits.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline and Time to Normalization of C-Reactive Protein
기간: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline and time to normalization of C-reactive protein among participants with elevated C-reactive protein at enrollment.
Normalization is defined according to the reference range of the performing laboratory.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline and Time to Normalization of Erythrocyte Sedimentation Rate
기간: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline and time to normalization of erythrocyte sedimentation rate among participants with elevated erythrocyte sedimentation rate at enrollment.
Normalization is defined according to the reference range of the performing laboratory.
|
Baseline through 12 months post-procedure
|
|
Proportion of Participants Achieving Biomarker Normalization
기간: Through 12 months post-procedure
|
Proportion of Participants Achieving Biomarker Normalization
|
Through 12 months post-procedure
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Adolph V. Lombardi, MD, Mount Carmel New Albany Surgical Hospital (JIS Orthopedics)
- 수석 연구원: Peter K Sculco, MD, Hospital of Special Surgery (New York)
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 7월 31일
기본 완료 (추정된)
2028년 8월 1일
연구 완료 (추정된)
2029년 8월 1일
연구 등록 날짜
최초 제출
2026년 7월 7일
QC 기준을 충족하는 최초 제출
2026년 7월 7일
처음 게시됨 (실제)
2026년 7월 14일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 7월 14일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 7일
마지막으로 확인됨
2026년 7월 1일
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- SOL-200-2025
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
예
미국에서 제조되어 미국에서 수출되는 제품
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .